公开(公告)号：US20240358809A1

公开(公告)日：2024-10-31

申请号：US18765553

申请日：2024-07-08

Applicant: Inovio Pharmaceuticals, Inc.

Inventor： Jian YAN ,  Anna SLAGER ,  Bradley GARMAN ,  Neil COOCH

IPC: A61K39/00 ,  A61K39/39 ,  A61P35/00 ,  C07K16/40 ,  C12N15/52 ,  C12N15/62

CPC classification number: A61K39/00115 ,  A61K39/39 ,  A61P35/00 ,  C07K16/40 ,  C12N15/52 ,  C12N15/62 ,  A61K2039/53 ,  A61K2039/55527 ,  A61K2039/575

Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens are disclosed. Methods of treating a subject with a Survivin-expressing tumor and methods of preventing a Survivin-expressing tumor are disclosed. Synthetic consensus Survivin antigens are disclosed.

公开(公告)号：US20240342305A1

公开(公告)日：2024-10-17

申请号：US18666163

申请日：2024-05-16

Applicant: CRAGE MEDICAL CO., LIMITED

Inventor： Huamao WANG ,  Bo SONG

IPC: A61K47/68 ,  A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63 ,  G01N33/574

CPC classification number: A61K47/6879 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/395 ,  A61K48/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/7151 ,  C07K16/2809 ,  C07K16/303 ,  C07K16/46 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63 ,  A61K2039/5156 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33 ,  G01N33/57438

Abstract: The present invention provides an antibody against glypican-3 (GPC3) and application thereof, and the antibody comprises a single chain antibody and humanized antibody.

公开(公告)号：US20240327805A1

公开(公告)日：2024-10-03

申请号：US18744124

申请日：2024-06-14

Applicant: Kevin Redding ,  Andrey Kanygin

Inventor： Kevin Redding ,  Andrey Kanygin

IPC: C12N9/02 ,  C07K14/405 ,  C12N1/12 ,  C12N15/62 ,  C12P3/00

CPC classification number: C12N9/0077 ,  C12N1/12 ,  C12N15/62 ,  C12P3/00 ,  C07K14/405 ,  C07K2319/00

Abstract: Provided herein, in some embodiments, are engineered cells and use of the same for increased hydrogen production. In particular, provided herein are genetically engineered cells comprising a polynucleotide encoding a fusion protein comprising a photosystem I (PSI) protein and an algal hydrogenase, as well as methods for producing such genetically engineered cells. Also provided herein are methods for increasing hydrogen (H2) production in cells.

公开(公告)号：US12098199B2

公开(公告)日：2024-09-24

申请号：US17522284

申请日：2021-11-09

Applicant: CRAGE medical Co., Limited

Inventor： Huamao Wang ,  Bo Song ,  Xiumei Cai

IPC: C07K16/28 ,  A61K35/17 ,  A61K48/00 ,  C07K14/705 ,  C07K14/725 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/867 ,  A61K35/12

CPC classification number: C07K16/28 ,  A61K35/17 ,  A61K48/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/867 ,  A61K2035/124 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70

Abstract: Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.

公开(公告)号：US20240294875A1

公开(公告)日：2024-09-05

申请号：US18658913

申请日：2024-05-08

Applicant: NantBio, Inc.

Inventor： Kayvan Niazi

IPC: C12N5/0783 ,  A61K35/17 ,  A61K38/17 ,  A61K45/06 ,  A61K48/00 ,  C07K14/725 ,  C12N15/62

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K38/1774 ,  A61K45/06 ,  C07K14/7051 ,  C12N15/62 ,  A61K48/00 ,  C12N2510/00

Abstract: Compositions, methods and uses of genetically modified NK cells to treat a patient with a tumor are presented. The genetically modified NK cells express a protein complex having an α chain and a β chain T cell receptor, at least a portion of which is specific to a patient- or tumor-specific neoepitope, or a tumor associated antigen, and at least a portion of CD3δ, and at least a portion of CD3γ. The genetically modified NK cells can be administered to a cancer patient to induce, maintain or augment a T cell immune response against the cancer or the tumor.

公开(公告)号：US20240279303A1

公开(公告)日：2024-08-22

申请号：US18597679

申请日：2024-03-06

Applicant: Surrozen Operating, Inc.

Inventor： Zhengjian ZHANG ,  Jennifer Jean BRADY ,  Aaron Ken SATO ,  Wen-Chen YEH ,  Yang LI ,  Teppei YAMAGUCHI

IPC: C07K14/705 ,  A61K47/65 ,  C07K14/47 ,  C07K16/28 ,  C07K16/40 ,  C12N15/62

CPC classification number: C07K14/705 ,  A61K47/65 ,  C07K14/47 ,  C07K16/2851 ,  C07K16/2881 ,  C07K16/40 ,  C12N15/62 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/75 ,  C07K2319/30

Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.

公开(公告)号：US12065666B2

公开(公告)日：2024-08-20

申请号：US16475412

申请日：2018-01-04

Applicant: Rutgers, the State University

Inventor： Shengkan Jin ,  Juan-Carlos Collantes

IPC: A61K31/7088 ,  A61K38/46 ,  A61K38/50 ,  A61K48/00 ,  C12N9/22 ,  C12N9/78 ,  C12N15/113 ,  C12N15/62 ,  C12N15/90

CPC classification number: C12N15/90 ,  A61K31/7088 ,  A61K38/465 ,  A61K38/50 ,  A61K48/00 ,  C12N9/22 ,  C12N9/78 ,  C12N15/113 ,  C12N15/62 ,  C07K2319/00 ,  C12N2310/20 ,  C12N2310/3519 ,  C12N2800/80

Abstract: The present invention discloses systems for targeted gene editing and related uses.

公开(公告)号：US12055538B2

公开(公告)日：2024-08-06

申请号：US17144776

申请日：2021-01-08

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Seiji Sakata ,  Yuki Togashi ,  Naoya Fujita ,  Ryohei Katayama

IPC: C07H21/04 ,  A61K31/519 ,  A61K38/00 ,  A61P35/00 ,  C07K14/82 ,  C12N9/12 ,  C12N9/88 ,  C12N15/113 ,  C12N15/62 ,  G01N33/50 ,  G01N33/574 ,  C12Q1/6853 ,  C12Q1/686 ,  C12Q1/6886

CPC classification number: G01N33/5011 ,  A61K31/519 ,  A61K38/005 ,  A61P35/00 ,  C07K14/82 ,  C12N9/12 ,  C12N9/88 ,  C12N15/113 ,  C12N15/62 ,  C12Y207/11025 ,  C12Y402/01047 ,  G01N33/57446 ,  C12Q1/6853 ,  C12Q1/686 ,  C12Q1/6886

Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

公开(公告)号：US20240254170A1

公开(公告)日：2024-08-01

申请号：US18594957

申请日：2024-03-04

Applicant: AgroSpheres, Inc.

Inventor： Ameer Hamza SHAKEEL ,  Sepehr ZOMORODI ,  Joseph Thomas FRANK ,  Zachery George DAVIS ,  Payam POURTAHERI

IPC: C07K14/195 ,  A01N25/28 ,  A01N63/22 ,  A01N63/50 ,  C07K14/32 ,  C07K14/335 ,  C07K14/34 ,  C12N1/08 ,  C12N9/52 ,  C12N9/54 ,  C12N15/62 ,  A61K39/108 ,  B01F101/04

CPC classification number: C07K14/195 ,  A01N25/28 ,  A01N63/22 ,  A01N63/50 ,  C07K14/32 ,  C07K14/335 ,  C07K14/34 ,  C12N1/08 ,  C12N9/52 ,  C12N9/54 ,  C12N15/62 ,  A61K39/0258 ,  B01F2101/04 ,  C07K2319/705

Abstract: The present disclosure is generally directed to an anucleated cell-based platforms for encapsulation and delivery of agricultural compounds. Disclosed herein are compositions for the stable and targeted delivery of agricultural compounds within achromosomal and/or anucleated cells. The present disclosure also provides methods of improving encapsulation and retention of agricultural compounds in achromosomal and/or anucleated cells.

公开(公告)号：US12049632B2

公开(公告)日：2024-07-30

申请号：US17339112

申请日：2021-06-04

Applicant: BIOCON LIMITED

Inventor： Nagaraj Govindappa ,  Kedarnath Sastry ,  Maria Melina Soares

IPC: C07K14/705 ,  A61K38/00 ,  A61K38/10 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K48/00 ,  C07K7/08 ,  C07K14/00 ,  C07K14/495 ,  C07K14/65 ,  C07K14/71 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/00 ,  C12N15/62 ,  G01N33/68

CPC classification number: C12N15/62 ,  A61K38/10 ,  A61K38/179 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/005 ,  C07K7/08 ,  C07K14/00 ,  C07K14/495 ,  C07K14/65 ,  C07K14/70532 ,  C07K14/70596 ,  C07K14/71 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0018 ,  G01N33/6854 ,  A61K38/00 ,  A61K2039/505 ,  A61K2121/00 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/732 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/33 ,  C12N2500/22

Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.